Exogenous testosterone is being aggressively marketed to men who feel tired, depressed, or have lower sex drive. However, recent studies have demonstrated that the use of exogenous testosterone to treat the condition drug manufacturers have named "Low T" can result in an increased risk of stroke, pulmonary embolism, myocardial infraction, and deep vein thrombosis. Currently, the labels for these drugs do not carry a warning for any of these adverse outcomes.
This Litigation Group provides a venue through which the most current and accurate information, documents and work product on medical literature, regulatory issues, and general and specific causation may be shared among AAJ members representing individuals who have suffered injuries as a result of exogenous testosterone by transdermal application or intramuscular injection.
This Litigation Group was formed in February 2014.
The Testosterone Therapy Litigation Group has a list server and a document library where members can share information, documents, and pertinent information as well as holds education programs.
AAJ Annual and Winter Conventions, or as needed by group members.